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ABSTRACT
Objectives: The GIOVE Study was aimed to the
achievement of allocative efficiency of the budget
allocated to the prevention of human papillomavirus
(HPV)-induced diseases. An ex-ante determination of
the most efficient allocation of resources between
screening and multicohort quadrivalent immunisation
programmes was followed by the ex-post assessment
of the allocative efficiency actually achieved after
a 12-month period.
Design: A bound optimisation model was developed to
determine the ex-ante allocative efficiency of
resources. The alternatives compared were the
screening programme alone and the quadrivalent
immunisation with access to screening. A sensitivity
analysis was carried out to assess the uncertainty
associated with the main inputs of the model.
Subsequently, a cohort of girls with a complete
recorded vaccination history were enrolled in an
observational retrospective study for 18 months to
ensure full compliance with the recommended
schedule of vaccination (0, 2, 6 months) within
a 12-month time horizon.
Setting: Basilicata region, in the south of Italy.
Participants: 12 848 girls aged 12, 15, 18 or 25 years.
Intervention: Immunisation with quadrivalent
anti-HPV vaccine.
Outcome measures: The vaccination coverage rate
was considered to be the indicator of the best
achievable benefit, given the budgetary constraints.
Results: Assuming a vaccine price of V100 per dose,
a vaccination coverage rate of 59.6% was required for
the most effective allocation of resources. The optimal
rate of coverage was initially in favour of the
multicohort strategy of vaccination against HPV
(72.8%62%). When the price paid for the quadrivalent
vaccine dropped to V85 per dose, the most efficient
coverage rate (69.5%) shifted closer to the
immunisation rate actually achieved during the
12-month observation period.
Conclusions: The bound optimisation model
demonstrated to be a useful approach to the ex-ante
allocation and the ex-post assessment of the resources
allocated to the implementation of a multicohort
quadrivalent anti-HPV vaccination programme. INTRODUCTION
Human papillomavirus (HPV)-induced
malignancies represent the second most
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ARTICLE SUMMARY
Article focus
- At present, screening and immunisation are
costeeffective strategies to reduce the death
toll of cervical HPV-related malignancies, which
in Italy alone amounts to 1200 women per year.
- While there are no evidences to reduce the
coverage of screening in favour of a wider
coverage of immunisation, the adoption of a
multicohort strategy of vaccination would allow a
larger proportion of the female population aged
between 12 and 25 years to be immunised in a
shorter period of time (6e8 years).
- A bound optimisation model was developed to
determine the allocative efficiency of the resources
used for the screening and the vaccination
programmes. Subsequently, an observational
retrospective study was carried out to verify the
degree of allocation efficiency actually attained
after implementation of the multicohort immunisa-
tion programme.
Key messages
- Using a vaccine price of V100 per dose,
a coverage rate of 59.6% was required for the
most effective allocation of resources. A sensi-
tivity analysis showed that when the price was
reduced to V85 per dose, the most efficient
coverage rate increased to 69.5%. A vaccination
coverage rate of 72.8%62.0% was observed.
- Although statistically significant, the observed
inefficiency was progressively reducing from
21% in the July 2007 to August 2008 period to
5% after September 2008, when the vaccine
price was reduced to V85 per dose.
- The bound optimisation model demonstrated to
be a useful approach to assess the allocative
efficiency of the resources budgeted to the
implementation of a multicohort quadrivalent
anti-HPV vaccination programme.
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common type of cancer in women worldwide.1 In Italy,
more than 3000e3500 new cases of cervical cancer
(which corresponds to an age-standardised rate of inci-
dence of between 7.7 and 8.1 cases per 100 000 women)
are diagnosed annually,2 3 and approximately 1200
women die from this disease every year.2 Overall, the
economic burden to the Italian National Health Service
that is caused by cervical HPV-related pathologies is
considerable, with the cost estimated to lie in the range
V200e250 million per year.4 5
A programme of screening for cervical cancer has
been implemented in Italy since 1996 to reduce the
incidence of cervical cancer and its associated mortality
rate. Women aged between 25 and 64 years are invited
for screening for cervical cancer every 3 years, with the
aim of achieving the early detection and treatment of
precancerous cervical lesions (cervical intraepithelial
neoplasia (CIN)) and preventing the onset of invasive
cervical cancer.6
In early 2007, a new tool became available to reduce
the incidence of HPV-related malignancies: the vaccine
in its bivalent and quadrivalent form. The coste
effectiveness of immunisation against HPV had been
previously demonstrated by a large number of modelling
studies.7e13 In one such study that was carried out in
Italy, the authors assessed the costeeffectiveness of a
programme of quadrivalent vaccination for a single
cohort of 12-year-old girls.14 In their model, the current
programme of screening (including the management of
HPV-related pathologies) was considered as a compara-
tive case. The results of their study suggested that the
introduction of a programme of vaccination using a
quadrivalent HPV vaccine alongside the current
programme of screening for cervical cancer in Italy
would produce an incremental costeeffectiveness ratio
of V12 303 per life year gained and V9569 per quality-
adjusted life year gained. An economic assessment of
the bivalent vaccine reported a cost of V26 361 per
quality-adjusted life year gained,15 which provided
further evidence that vaccination against HPV is
currently significantly below the threshold value of
V30 000e45 000 that is used commonly to determine
‘value for money’ in health interventions.16 17 The
difference in the economic evaluation of the two
anti-HPV vaccines were mostly determined by the quad-
rivalent’s efficacy in preventing anogenital warts, a non-
life-threatening HPV-induced disease.
More favourable economic results were obtained using
predictive models that were based on a quadrivalent
multicohort strategy of vaccination (three to four
cohorts).18 When a multicohort strategy of vaccination is
adopted, a larger proportion of the female population
aged between 12 and 25 years can be vaccinated in a
shorter period of time (5e8 years) and an early reduc-
tion of costs can be expected. A multicohort programme
of vaccination using the quadrivalent vaccine was asso-
ciated with a total saving of approximately V132 million,
as a result of a reduction in the numbers of low-grade
and high-grade cervical lesions, anogenital warts and
invasive cervical cancers (table 1).21
In July 2007, a decree issued by the State-Regions
Conference granted access to quadrivalent vaccination
against HPV, which should mandatorily be both free of
charge and promoted actively, at least in the cohort
of girls aged 12 years, with the progressive achievement
of a rate of coverage of 95% in the next 5 years. The
decree was resolving the uncertainty related to the
ARTICLE SUMMARY
Strengths and limitations of this study
- The relevance of this study is enhanced by its internal validity:
the sample size was significant (over 12 000 girls enrolled) and
coherent (all subjects enrolled were coming from the same
region); the observation time allowed to cover the entire
immunisation cycle; individual data related to vaccination
(including all costs incurred) were complete and accurate
(provided by the Regional Health Authority); the bound
optimisation model adequately described the available
competing choices: immunisation versus screening.
- The bound optimisation model is subject to the condition that
the programmes evaluated are completely divisible, with
constant return to scale and that every subject included
receives a fraction of the total expected benefit. Nonetheless,
these limitations do not seem to affect the generalisability of
the research outcomes.
Table 1 Projected outcomes averted by means of the quadrivalent vaccine and expected reductions in expenditure
Outcomes
Annual expected
number of events
Number of events prevented
with the quadrivalent vaccine
Reduction in
expenditure (V million)
Abnormal pap smears 415 000 258 337 3.8
Colposcopies 116 000 76 909 19.2
LSIL and ASCUS 91000 56 648 22.7
HSIL 13 700 9097 8.2
Cervical cancer 4000 2988 49.9
Genital warts 125 000 115 625 27.8
Total 764 700 519 604 131.6
In this multicohort model, a vaccination coverage rate of 80% was assumed.19 20 Reductions were calculated at the peak efficiency of the
vaccination programme. A cross-protection effect of the quadrivalent vaccine was also considered.
ASCUS, Atypical Squamous Cells of Undetermined Significance; HSIL, High-grade Squamous Intraepithelial Lesions; LSIL, Low-grade
Squamous Intraepithelial Lesion.
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choice of the vaccine (quadrivalent) and the priority of
cohort to be immunised (12-year-old girls), but the actual
modalities of implementation of the immunisation
campaign were delegated to individual regions, under the
constraint that the incremental cost of the anti-HPV
vaccination would be funded within a budget previously
allocated to healthcare. In order to maximise the net
benefits or utilities to public health that can be derived
from a proposed decision, it is essential to allocate
resources as efficiently as possible, in full compliance with
the universal principles of equity of access to treatment.22
The policy makers of the Basilicata region, in the
south of Italy, became concerned about the potential
issues of equality and allocative efficiency of resources
raised by the choices at hand.
A downsize of the current screening programme could
potentially increase the risk of HPV-related malignan-
cies, in the light of the lack of information about the
impact of immunisation on the coverage and frequency
of screening. In time, women vaccinated in the multi-
cohort immunisation programme would enter the age
group 25e64 years and thus should still be considered
eligible for screening. The option to reduce the
resources dedicated to screening would therefore be
unethical and, ultimately, it would be likely to have an
adverse effect on the women’s welfare.
On the other hand, the implementation of a quadri-
valent multicohort strategy of vaccination in the region
could provide clinical and economic benefits 5e8 years
earlier than would be expected with the 12-year-old
single-cohort strategy made mandatory by the national
guidelines. It should be considered, though, that the
validity of costeeffective studies is strongly dependent
on the accuracy of complex models, based on hundreds
of assumptions often derived by sparse sources. In spite
of the prescriptive nature of health economic outcomes,
they cannot completely resolve the uncertainty at the
time of the investment decision, determined by the lack
of information on population-wide efficacy of the anti-
HPV vaccine in the long term. Moreover, a multicohort
vaccination strategy would increase the complexity of the
immunisation programme, whose rate of implementa-
tion represents an unknown variable itself in the simpler
one-cohort model.
After a number of consultations, the healthcare policy
makers of the Basilicata region made the following
implementation choices:
< To adopt a four-cohort immunisation strategy
targeting women who were born in 1983, 1990, 1993
and 1997. Data on vaccination coverage rates by
cohort are reported in table 2.
< To maintain the coverage rate (women aged between
25 and 64 years) and the frequency (3 years) of the
screening programme.
< To allocate a maximum allowable budget for 2007/
2008 to finance both the screening and the immuni-
sation programmes of V2.5 million.
These constraints were added ex-ante to the choice of
the quadrivalent anti-HPV vaccine and the long-term
target coverage for the 12-year-old cohort of girls (95%
in 5 years), which were mandated by Law (Ministry of
Health) at national level.
The objective of this study was to support the health-
care management of the Basilicata region to achieve the
allocative efficiency of the allowable budget assigned to
anti-HPV screening and quadrivalent immunisation
programmes. In general terms, the allocative efficiency
of a budget between two healthcare programmes is
reached when the population welfare is maximised.23 As
this particular budget was earmarked to prevent HPV-
related malignancies, its allocative efficiency would be
reached when the number of HPV-related events is
minimised, given three additional conditions: no change
in the frequency and coverage of the current screening
programme, a multicohort modality of implementation
of the new immunisation programme and the achieve-
ment of the target coverage required by the national
guidelines for the cohort of 12-year-old girls. A further
Table 2 Data on vaccination rates provided by the Basilicata region and included in the bound optimisation model
Cohort 1996 Cohort 1993 Cohort 1990 Cohort 1983 All cohorts
Girls eligible for vaccination 2785 3064 3426 3573 12 848
Vaccinated in LHA 1 414 456 519 272 1661
Vaccinated in LHA 2 825 857 873 739 3294
Vaccinated in LHA 3 278 295 361 234 1168
Vaccinated in LHA 4 502 470 579 370 1921
Vaccinated in LHA 5 341 371 344 249 1305
Total vaccinated 2360 2449 2676 1864 9349
Vaccination coverage rate (%) 84.7 79.9 78.1 52.2 72.8
SD (%) 2.0 4.3 3.4 3.1 2.0
Differences in vaccination coverage rates were statistically significant between cohorts (p<0.0001). Overall, the vaccination coverage rate
reached 72.8%62.0% after 12 months. The highest vaccination coverage rate was reported in the cohort of girls aged 12 years (84.7%62.0%).
However, it should be noted that similar values were recorded in the two chronologically subsequent cohorts (15 and 18 years) with rates of
79.9%64.3% and 78.1%63.4% for girls aged 15 and 18 years, respectively. In contrast, a statistically significantly lower coverage rate (52.1%6
3.1%) was observed in the cohort of women aged 25 years. This rate was significantly below the average value of 72.8% (p<0.0001) and was
also significantly less than the value required to achieve the allocative efficiency predicted by the bound optimisation model (p<0.001).
LHA, Local Health Authority.
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condition required by allocative efficiency is that the
allowable budget is entirely spent. To date, no studies
have examined specifically the level of allocative effi-
ciency of resources assigned to programmes of vaccina-
tion against HPV. In order to provide quantitative
guidelines relevant to managerial decision, the main
objective of the study was further divided into two
complementary outcomes:
1. Objective ex-ante: the determination of the most
efficient allocation of resources between the
screening and the multicohort quadrivalent immuni-
sation programme, given the constraints discussed
above.
2. Objective ex-post: the assessment of the allocative
efficiency actually achieved by the screening and the
quadrivalent immunisation programmes 12 months
after the beginning of its implementation (July 2007).
The research outcomes were strictly dependent upon
the given constraints stipulated ex-ante by political
choices made at regional level, namely the choice of the
quadrivalent anti-HPV vaccine, the multicohort immu-
nisation strategy and the frequency and coverage of
screening. It was beyond the scope of this paper
to determine and compare the allocative efficiency of
alternative scenarios based on different constraints
(eg, the choice of the bivalent anti-HPV vaccine, a single-
cohort immunisation strategy or a different frequency
and coverage of the screening programme). The sensi-
tivity analysis reported in the discussion of the results
provides an indication of the sensitivity of allocation
efficiency to the main parameters taken into consider-
ation, including the allowable budget, the size of the
female population eligible for immunisation and/or
screening, the annual cost of immunisation and
screening and their relative efficacy in preventing HPV-
related diseases, such as abnormal Pap smears, precan-
cerous cervical lesions (CIN1, CIN2e3), invasive cervical
cancer and anogenital warts.
METHODS
Ex-ante objective: the determination of the allocative
efficiency of the allowable budget between screening and
quadrivalent multicohort vaccination
The bound optimisation model
The bound optimisation model was adopted in view of
the fact that a number of ex-ante constraints could be
taken into account in the allocation of resources among
healthcare programmes. The bound optimisation model
was developed by Weinstein and Zeckhauser24 and
further modified by Garber and Phelps.25 It allows
makers of health policy to maximise the total expected
benefits for a given budget. We used an adapted version
of this model widely used in our previous analyses.19 26
The general problem of bound optimisation proposed
in this study can be described as follows: we wish to
choose dI to maximise.
J ¼ +Mi¼1dix1i (1)
subject to constraint +Mi¼1dix
2
i # R and
0#di#1ði ¼ 1;.;MÞ
In (1), x1i is the consequential expected benefit from
every alternative i. di represents, instead, the fraction of
every alternative that should be chosen. The constraints
point out as the amount of the costs x2i associated to the
select alternatives must be smaller or equal to the avail-
able general budget R. The optimal values of di are data
from a resolution from the equation of this form:
di ¼
8>>>><
>>>>:
1 if
x1i
x21
> l;
0 if
x1i
x21
< l;
p if
x1i
x21
¼ l; 0< p< 1
(2)
where l is defined as the critical ratio (ie, the optimal
proportion for every of the considered alternatives) of
the problem of bound optimisation.
Formulation of the problem
In the model that we adapted, x1 represents screening,
x2 is the combination of vaccination and screening and
the parameter Ei(i¼1,2) denotes the expected benefit of
each alternative. B is the budget, and l and m are the
so-called critical values (ie, the optimal proportions of
the alternatives considered). The vaccination coverage
rate was considered to be an indicator of the best
achievable benefit, given the budgetary constraints in
Basilicata. The alternatives compared in the study were
as follows:
< The screening programme (x1) for the early detec-
tion of cervical cancer (ie, secondary prevention). In
Italy, organised screening is based on the Pap smear
test, which is currently recommended to be carried
out every 3 years;
< The quadrivalent programme of vaccination (x2)
associated with access to screening for cervical
cancer for the four cohorts of women eligible to be
included in the multicohort vaccination programme.
In the present context, the bound optimisation model
requires the following data:
< Annual cost of each alternative. Only annual direct
costs were included in the analysis due to the lack of
data on indirect costs associated with the prevention
of HPV-related malignancies in Italy. The annual cost
of screening (C1) includes the cost of outpatient visits
and the materials used to perform the Pap smear test.
The combined annual cost of vaccination and
screening (C1 + C2) also includes the cost of the
vaccine.
< Annual budget available for the primary and
secondary prevention of HPV-related diseases. The
screening component was calculated using the 2007/
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2008 average value budgeted by the Regional Health
Service for Pap tests. The annual budget allocated to
the four-cohort strategy of vaccination and to the
associated programme of screening in Basilicata was
V2.5 million. As the analysis refers to an actual
12-month time period, both cost and budget values
have not been discounted.
< Size of female population eligible for vaccination and
inclusion (denominator of x1). All girls in the Basilicata
region who were born in 1996, 1993, 1990 or 1983 and
who were still alive in July 2007 were taken into account.
< Expected benefit of each of the two alternatives (Ei).
Using recently published Italian data,14 18 21 the
annual number of cervical events induced by HPV, as
well as the number averted by both the screening and
the quadrivalent vaccine (using a three-cohort
strategy of vaccination), were estimated. These cases
were related to the pertinent female population of
2006 (provided by the Italian National Institute of
StatisticsdISTAT20). The number of events was
assumed to be unaffected by the inclusion of the
fourth cohort (women aged 25 years). The propor-
tion of cases of disease and of cases where disease was
avoided was assessed for the whole Italian population.
The expected benefit weighted by both demographics
and the frequency of disease was calculated using the
following formulae:
E1 ¼ 1+
k

Ak
P
3
Ak
TotðAk


3100
E2 ¼ 1+
k

Dk
P
3
Dk
TotðDkÞ

3100;
where Ak and Dk represent the number of women
assigned to the two alternative options (screening alone
or vaccination and screening in combination, respec-
tively), P is the female population of Italy on 1 January
2006, and the index k represents the different HPV-
related diseases, such as abnormal Pap smears, precan-
cerous cervical lesions (CIN1, CIN2e3), invasive cervical
cancer and anogenital warts. The incidence of HPV-
related diseases that would occur with screening alone
and with vaccination and screening corresponded to
90.77 and 36.94 per 10000 women, respectively. The
equations represent the weighted expected benefit of
screening alone (E1) and of vaccination and screening
(E2), expressed in percentage terms as the difference
between the unit (100%) and the incidence of HPV-
related diseases associated with each of the two alterna-
tive strategies. It is worth noting that screening alone has
no effect on the detection of anogenital warts.
Ex-post objective: the assessment of the allocative
efficiency actually achieved by the screening and the
quadrivalent immunisation programmes 12 months after the
beginning of its implementation (July 2007)
An observational and retrospective data collection was
designed to assess the allocative efficiency of the two
programmes. All girls in the Basilicata region who had
a recorded vaccination and who belonged to one of the
four selected cohorts (aged 12, 15, 18 and 25 years in
2007) were considered to be eligible for enrolment. Girls
who had an incomplete record of vaccination were
excluded. The collection of data began in July 2007 and
continued for 18 months to ensure full compliance with
the recommended schedule of vaccination (0, 2,
6 months) within a 12-month time horizon.
Sources of data
Data on rates of screening and vaccination, allocation of
budgets and costs (including the total spent on preven-
tion) were obtained directly from each of the five
participating Local Healthcare Authoritiesi, all of which
fall within the remit of the region. The data were related
to the period from January 2007 to December 2008. The
cost of a full course of quadrivalent vaccination (three
doses) was V315, including the costs of administering
the vaccine.
The regional demographic archive provided informa-
tion on subjects’ date of birth, sex and healthcare
identification number, whereas data on the course of
vaccination (including the patients’ names and health-
care identification numbers, together with dates of issue,
brand names and batch numbers of the vaccine) were
obtained from the regional vaccination register. All
personal data were replaced with a univocal numerical
code, which ensured that both archives were anonymous
at source (in full compliance with the Italian Privacy
LawdDecree 196, 30 June 2003). The observational and
retrospective design of this data collection did not
necessitate the collection of informed consent from the
subjects.
Statistical analysis
Differences among groups were tested using one-way
analysis of variance for continuous variables, while
Pearson’s c2 test was used for categorical variables. All
the tests were two tailed, and p values that were <0.05
were considered to be statistically significant. Sensitivity
analyses were performed to assess the uncertainties
associated with the estimates of allocative efficiency.
Specifically, we varied the cost of the quadrivalent
vaccine by reducing it by 15%twice and both increased
and reduced the budget by 10%. This is because changes
of such an order of magnitude are fairly likely to occur.
The bound optimisation model and the sensitivity anal-
yses were carried out using Mathematica, V.6.0, and the
statistical analyses were performed using SPSS for
Windows, V.16 (2002).
RESULTS AND DISCUSSION
The mean weighted benefit of the combined prevention
strategy (vaccination and screening) resulted significantly
iThe Local Health Authority is a body delegated by the Italian National
Health Service to deliver local healthcare services, commonly at
provincial level.
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higher than that of screening alone (91% vs 37% of
cervical HPV-related events averted, respectively). For
a vaccine cost of V100 per dose, the results show that the
vaccination coverage rate should have reached a level of
59.6% to achieve an efficient allocation of resources.
The decision makers of the Basilicata region conse-
quently set a target rate of coverage of 60% for the
quadrivalent multicohort immunisation programme.
Twelve months after the beginning of the immunisa-
tion programme, the actual rate of coverage reached
72.8%62.0%. This figure is 21% higher than the
regional public health target with a difference that was
statistically significant (p<0.001).
The highest vaccination coverage rate was reported in
the cohort of girls aged 12 years (84.7%62.0%).
However, it should be noted that similar values were
Figure 1 Sensitivity analysis of
allocative efficiency performed on
the basis of variations in the main
parameters implied in the bound
optimisation model. Figure shows
the optimal rate of coverage is
highly elastic to large reductions in
price of the anti-human
papillomavirus (HPV) vaccine of
choice, almost linearly elastic to
changes in total budget and
population eligible for anti-HPV
prevention programmes and
virtually inelastic to the cost of
screening.
Figure 2 Sensitivity analysis of
allocative efficiency performed on
the basis of variations in budget
and cost of vaccine. Figure shows
the general case where, by using
an optimisation procedure, the
authorities in Basilicata could
maintain the current high rate of
coverage with a reduced budget
(equivalent to a reduction in the
cost of the vaccine from V85, point
a, to V72.5 per dose, point b).
Alternatively, the rate of coverage
could be reduced to the optimal
value of 69%, thereby achieving
the concomitant savings (point g).
Further reductions in price, as
reflected in the progression
towards point d, should provide
scope for savings that can be
represented by the shaded area
(agd). In this way, regional
decision makers could authorise
the reallocation of resources to
other programmes of prevention,
while maintaining the expected
high level of efficiency of the planned programme of vaccination against human papillomavirus. Regional authorities might also
decide to reduce the allocated budget by 10%. In such scenario, although the intercept is still within the boundary of the allocative
efficiency curve, an immediate mean decrease of vaccination coverage rate of 10.1%60.9% would be observed. This would have
the knock-on effect of reducing some of the clinical benefits.
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recorded in the two chronologically subsequent cohorts
(15 and 18 years) with rates of 79.9%64.3% and 78.1%6
3.4% for girls aged 15 and 18 years, respectively. In
contrast, a statistically significantly lower coverage rate
(52.1%63.1%) was observed in the cohort of women
aged 25 years. This rate was significantly below the
average value of 72.8% (p<0.0001) and was also signifi-
cantly less than the value required to achieve the allo-
cative efficiency predicted by the bound optimisation
model (p<0.001).
Based on a sensitivity analysis performed on the bound
optimisation model, figure 1 shows that the optimal rate
of coverage is highly elastic to large reductions in price
of the anti-HPV vaccine of choice, almost linearly elastic
to changes in total budget and population eligible for
anti-HPV prevention programmes and virtually inelastic
to the cost of screening. This is mostly due to the
inelasticity of the optimal coverage to marginal changes
in the efficacy of immunisation and screening in
preventing HPV-related diseases, estimated in the model
as 91% and 37%, respectively.
In the unlikely scenario where the screening
programme resulted more effective than the anti-HPV
vaccination, then the vaccination coverage would drop
to 0%.
The optimal rate of coverage was initially exceeded in
the Basilicata region when the multicohort strategy of
vaccination against HPV was used, achieving an actual
inefficient allocation of resources between screening and
vaccination, in favour of the second. If the price of the
vaccine were to be reduced to V85 per dose, the optimal
rate of vaccination coverage would increase to 69.5% (see
point g in figure 2). As a matter of fact, in September
2008, the price paid for the quadrivalent vaccine by the
Basilicata region dropped to V85 per dose.
Figure 2 shows the general case where, by using an
optimisation procedure, the authorities in Basilicata
could maintain the current high rate of coverage with
a reduced budget (equivalent to a reduction in the cost
of the vaccine from V85, point a, to V72.5 per dose,
point b). Alternatively, the rate of coverage could be
reduced to the optimal value of 69%, thereby achieving
the concomitant savings (point g).
Further reductions in price, as reflected in the
progression towards point d, should provide scope for
savings that can be represented by the shaded area
(agd). In this way, regional decision makers could
authorise the reallocation of resources to other
programmes of prevention, while maintaining the
expected high level of allocative efficiency of the budget
allocated to the prevention of HPV-related pathologies.
Regional authorities might also decide to reduce the
allocated budget by 10%. In such scenario, although the
intercept is still within the boundary of the allocative
efficiency curve in figure 2, an immediate mean decrease
of vaccination coverage rate of 10.1%60.9% would be
observed. This would have the knock-on effect of
reducing some of the expected benefits.
Our findings for the 12-month period of our study
demonstrate that the Basilicata region was able to
leverage the reduction in the price of the vaccine from
V100 to V85 per phial to achieve an higher than
planned coverage rate (73% vs 60%), progressively
reducing the inefficiency of the actual resource alloca-
tion to the quadrivalent multicohort vaccination from
21% in the period July 2007 to August 2008 to an almost
negligible 5% after September 2008, when the price
reduction came into effect. In the context of the Italian
national programme of vaccination, the Basilicata region
is in full compliance with the guidelines established by
Figure 3 Relationship between
coverage rate and number of
cohorts vaccinated.21 Figure
illustrates the expected long-term
effect of the vaccination,
correlated to the number of
cohorts targeted. The combined
reduction of all events, such as
abnormal Pap smears,
colposcopies, Atypical Squamous
Cells of Undetermined
Significance, Low-grade
Squamous Intraepithelial Lesion,
High-grade Squamous
Intraepithelial Lesions, cervical
cancer and genital warts, showed
a significant difference between
the second and the third cohort.
The vaccination of three to four
cohorts was likely to enhance the
percentage of events avoided,
shortening the time required to
reach the optimal cost/effective
outcome.
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the Italian State-Regions Conference, which in turn were
determined in accordance with both the Ministry of
Health and the National Institute of Health. Moreover,
the implementation of a multicohort strategy of vaccina-
tion in the region should provide clinical and economic
benefits 5e8 years earlier than would be expected with
a single-cohort strategy. Figure 3 provides an explanation
of the benefits associated with the multicohort
programme. Our findings are consistent with those of
a modelling study published in 2008,18 which demon-
strated that the greater flexibility in the rate of coverage
that results from vaccinating between three and four
cohorts rather than one (in the range 63.0%e72.0% for
a four-cohort strategy compared with a range of 78.0%e
83.5% for a two-cohort strategy) enables a higher
efficiency of vaccination to be maintained.21
The present study does have some limitations. The
bound optimisation model is subject to the condition
that the programmes evaluated are completely divisible,
with constant return to scale and that every subject
included receives a fraction of the total expected benefit.
Concerning the first condition, although we cannot
assume that healthcare programmes are completely
divisible, we can assume that there are sufficiently many
interventions that each one is small in value compared
with the whole: thus, the expected value is approximately
a continuum.24 The return to scale of anti-HPV immu-
nisation is unlikely to be constant due to the effect of
herd immunity,27 although at present no epidemiolog-
ical data are available to confirm a non-linear relation-
ship between coverage and expected reduction of
events. In essence, the effect of heard immunity on the
bound optimisation model is similar to a reduction in
price of the vaccine, by providing further reduction of
events at the same level of vaccination coverage.
Although this effect should presumably be more relevant
for levels of coverage below the optimal threshold esti-
mated by the bound optimisation level (59.6%), the
possibility to quantify the incremental reduction of HPV-
induced events as a function of vaccination coverage
would allow to estimate more precisely the optimal
allocation of resources between immunisation and
coverage. We can still assume that the return to scale of
the anti-HPV immunisation is constant within the ranges
taken into consideration to determine the allocative
efficiency of the allowable budget. Lastly, the third
condition is fully respected since every woman included
in the study maintains the access to the screening
programme, so she will receive a fraction of the expected
benefit.
Lastly, a major limitation of the adopted model is
embedded in its static and deterministic design, while
a statistical dynamic approach would further improve
the reliability of the outcomes.
CONCLUSIONS
The use of the Bound Optimisation Model was found to
be a very useful and rational approach to the determi-
nation of the optimal budget allocation given a number
of ex-ante constraints as well as the ex-post, short-term
assessment of the governance of resources allocated by
the Basilicata region to the implementation of a multi-
cohort programme of quadrivalent vaccination against
HPV. However, the model does not resolve all the issues
related to the costeeffectiveness of such programmes of
vaccination. Therefore, further probabilistic models or
observational studies using measured outcomes are
required. These should be designed specifically to
minimise the uncertainties associated with the large
number of variables that need to be considered in such
a complex problem.
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